Results 51 to 60 of about 218,564 (299)

Five mucosal transcripts of interest in ulcerative colitis identified by quantitative real-time PCR: a prospective study

open access: yesBMC Gastroenterology, 2008
Background The cause and pathophysiology of ulcerative colitis are both mainly unknown. We have previously used whole-genome microarray technique on biopsies obtained from patients with ulcerative colitis to identifiy 5 changed mucosal transcripts.
Kvifors Eva   +4 more
doaj   +1 more source

Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab [PDF]

open access: yes, 2019
Suppressor of Tumorigenicity 2 (ST2) is an IL33 receptor detected in the mucosa and serum of ulcerative colitis (UC) patients. We evaluated soluble ST2 (sST2) as a surrogate biomarker of disease outcome and therapeutic response, in moderate-to-severe UC ...
Diogo Branquinho   +22 more
core   +3 more sources

Psychological stress and eating behaviors as interacting influences on patient–reported disease activity in Italian patients with inflammatory bowel disease

open access: yesScientific Reports
Diet and psychological stress are recognized contributors to inflammatory bowel disease (IBD), yet their interaction—particularly stress-induced eating—remains underexplored.
Dilara Usta   +8 more
doaj   +1 more source

Molecular mechanism of Huaihuasan in treatment of ulcerative colitis based on network pharmacology and molecular docking

open access: yesPhytomedicine Plus, 2021
Background: Huaihuasan (HHS) is a Traditional Chinese Medicine formula for ulcerative colitis (UC). However, the pharmacology and molecular mechanism of HHS on ulcerative colitis still unclear.
Yi Wu   +3 more
doaj   +1 more source

Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. [PDF]

open access: yes, 2009
Ulcerative colitis is a chronic inflammatory disease of the colon that presents as diarrhea and gastrointestinal bleeding. We performed a genome-wide association study using DNA samples from 1,052 individuals with ulcerative colitis and preexisting data ...
Abraham, Clara   +33 more
core  

Differential expression of prolyl hydroxylase 1 in patients with ulcerative colitis versus patients with Crohn's disease/infectious colitis and healthy controls [PDF]

open access: yes, 2013
Background: Inhibition of prolyl hydroxylases (PHDs) leads to the induction of a transcriptional program that, in the gut, promotes intestinal epithelial cell survival.
De Vos, Martine   +4 more
core   +2 more sources

UiO‐66 metal–organic frameworks in biomedicine: From structural tunability to bioimaging, photodiagnostics, and photodynamic cancer therapy

open access: yesFEBS Open Bio, EarlyView.
UiO‐66(Zr) metal–organic frameworks are chemically stable, biocompatible, and highly tunable nanomaterials. Their modular structure enables controlled drug delivery, multimodal bioimaging, and light‐activated photodynamic therapy, supporting integrated diagnostic and therapeutic (theranostic) applications in cancer and biomedical research.
Veronika Huntošová   +2 more
wiley   +1 more source

Disease Burden and Unmet Medical Needs in Patients with Ulcerative Colitis in Greece: A Cross-Sectional Patient Survey

open access: yesMedical Sciences
Background: Ulcerative colitis (UC) requires life-long disease management. This study aimed to investigate the disease burden and unmet medical needs in UC patients in Greece.
George Gourzoulidis   +4 more
doaj   +1 more source

Macrophage-Biomimetic Nanoparticles Ameliorate Ulcerative Colitis through Reducing Inflammatory Factors Expression

open access: yesJournal of Innate Immunity, 2021
Background and Aims: Inflammatory mediator S100A9 is dramatically elevated in ulcerative colitis and correlates with disease severity. S100A9 is a potential molecule to target for the treatment of colitis, but to date, there is no effective targeting ...
Zhengshuo Li   +8 more
doaj   +1 more source

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy